CJC-1295 without DAC / Ipamorelin combines a shorter-acting growth-hormone-releasing hormone analogue with ipamorelin. Both ingredients are intended to encourage the body’s own release through different signaling pathways. The without- ingredient supplies a shorter-lived request for growth hormone release, while ipamorelin adds a signal through a different pathway. This combination is relevant to research on brief stimulation of the body’s own hormone-release system. Picture two communication lines sending requests to the same factory. Their combined effect cannot be assumed to reproduce the timing or size of the body’s natural growth hormone bursts.
SOURCE REFERENCE
Mixing and dose chart
Current aggregated data suggests the following information:
Each row shows a separate source example for CJC/IPA.
Bacteriostatic water is a source assumption. Amounts and schedules are not independently verified or personal medical advice. Consult a qualified clinician.
Peptide per Vial (mg)
BAC water
Dose
U-100 syringe
Reported frequency
10 mg(5 mg & 5 mg)
2 mL
0.5 mg
10 UNITS
Once daily 5 days per week, preferably before bed on an empty stomach.
10 mg(5 mg & 5 mg)
3 mL
0.5 mg
15 UNITS
Once daily 5 days per week, preferably before bed on an empty stomach.
CJC-1295 without DAC / Ipamorelin (CJC\IPA): Scientific Perspectives
This explains the rationale, not a demonstrated benefit of the finished blend. Evidence on individual ingredients does not establish the combination’s long-term safety or effectiveness. [6, 7]
Mechanism, evidence and interpretation
The CJC component targets the growth-hormone-releasing hormone pathway; ipamorelin targets the pathway. The combination is intended to stimulate release through two different inputs.
This explains the rationale, not a demonstrated benefit of the finished blend. Evidence on individual ingredients does not establish the combination’s long-term safety or effectiveness. [6, 7]
(10 mg & 10 mg)
3 mL
0.5 mg
6 UNITS
Once daily 5 days per week, preferably before bed on an empty stomach.
20 mg(10 mg & 10 mg)
5 mL
0.5 mg
10 UNITS
Once daily 5 days per week, preferably before bed on an empty stomach.
THE DOSING REFERENCE
Dosing instructions
Amounts, schedules, and preparation - organized and summarized from current aggregated data
4 protocols
01
SOURCE PROTOCOL
CJC/IPA(CJC-1295 without DAC & Ipamorelin) · 10 mg / 2 mL BAC water
Record every component, sequence, ratio and . A study of one ingredient does not establish efficacy, stability or interaction effects of the combination. A useful comparison would test the complete blend against its components and an appropriate control.
The duration of the CJC component does not establish the complete blend’s pharmacokinetic or GH-secretion profile. Studies would need to measure exposure to both ingredients and use serial GH sampling to characterize pulse frequency, amplitude and baseline secretion. Demonstrating that a compound stimulates endogenous GH is not equivalent to demonstrating a physiological secretion pattern or superiority to the form. [6, 7, 46, 48]
What the blend name identifies
CJC/IPA combines a CJC-related with ipamorelin. The abbreviation is a convenient product label, but it is not a complete specification. It does not by itself identify whether the CJC component has , whether it is modified GRF 1-29, or how much of each ingredient is present. The source records on this profile include no-DAC descriptions and different blend-strength labels. Those differences should remain visible rather than being averaged into one apparently precise instruction.
The two components are intended to influence release through different pathways. CJC-1295 belongs to the discussion, while ipamorelin belongs to the receptor discussion. Combining those ideas creates a research hypothesis. It does not create a new body of clinical evidence automatically, and the word blend should not be read as a guarantee that the ingredients work better together.
Why two pathways are discussed together
and -related signals can both influence release. They operate through different and interact with the body's inhibitory signals and feedback. Researchers have investigated combined stimulation within hormone physiology. This provides a reason to study a combination, but a larger hormone response is only one possible measurement. It does not determine the effect on strength, body fat, sleep or injury recovery.
The CJC component's duration is especially relevant. -binding CJC-1295 with DAC has a different exposure pattern from a no- preparation. A claim based on the long-acting trials cannot be used as though it directly tested the shorter-acting blend. The ipamorelin component introduces its own concentration and delivery questions. To interpret a mixture, the reader needs both chemical identities, the proportion of each, the route and the actually used in the study.
What component research can establish
Published CJC-1295 trials demonstrate hormone stimulation by a defined long-acting molecule in healthy adults. The original ipamorelin pharmacology work demonstrates release-pathway activity and a selective experimental hormone profile. A human ipamorelin trial addressed bowel recovery after surgery using intravenous treatment. None of these studies, by itself, establishes the effectiveness of a retail CJC/IPA blend for healthy adults seeking improved physique or recovery.
This is a common evidence-transfer problem. If ingredient A changes a marker and ingredient B changes a marker, the combination still needs testing. The mixture could produce a different exposure, stability, tolerability or balance of effects. A credible trial would describe the blend precisely, compare it with suitable controls and measure a meaningful outcome. Without that information, an assertion of synergy is a proposal to investigate, rather than a confirmed property of the finished product.
The amount printed for a blend can refer to total combined mass or to separate amounts of each component. Those are different descriptions. An arithmetic conversion can only work from clearly stated quantities, and it cannot repair an ambiguous ingredient label. Historical source variants on this page are kept separately for that reason. Compare the component profiles and check the exact variant before interpreting a schedule. Similar names and shared marketing categories should never replace the missing specification.
How the growth hormone system works
The system is a conversation between several organs. The , a small region at the base of the brain, sends signals to the . One signal, , encourages growth hormone release. Another, , restrains it. and related signals can also affect release. The pituitary does not normally produce one steady hormone level. It releases pulses, whose size and timing change with sleep, age, nutrition and other conditions. This explains why one isolated blood measurement can be difficult to interpret.
acts directly on some tissues and also encourages production of in the liver and elsewhere. These signals influence growth, protein turnover and the use of stored energy. The same network also affects blood glucose. A compound that raises a hormone measurement has therefore changed a real biological system, but the measurement alone cannot tell us whether someone became stronger, recovered from an injury, or lived longer. Those are separate outcomes that require separate studies.
It helps to distinguish three intervention points. A asks the to release hormone through the GHRH . A receptor reaches the release system through a different receptor. An analog acts further downstream, rather than simply asking the pituitary to work harder. These differences matter when comparing sermorelin, ipamorelin and IGF-1 LR3. Similar marketing descriptions do not make these substances interchangeable.
Feedback also matters. Circulating hormones can reduce further stimulation, and can change their response during repeated exposure. A stronger initial response does not guarantee a stronger continuing benefit. Body composition measurements need careful reading too: includes water and other nonfat tissues, not just contractile muscle. A trial should therefore report functional outcomes, such as measured strength or walking ability, alongside hormone levels and body composition. Without that context, a biochemical change can sound much more useful than the evidence actually demonstrates.
Timing also changes what a measurement means. A peak concentration describes one moment, while overall exposure describes a period of time. Sampling immediately after a stimulus can produce a different impression from sampling between pulses. Researchers may therefore use repeated blood draws rather than one isolated result. This does not make every high value desirable; it makes the interpretation more precise. For a release-pathway compound, the relevant question is how the intervention changes the pattern and whether that change produces an outcome that matters, compared with an appropriate control group.
How to read the research and dosing record
The dosing record above and this article serve different purposes. The record preserves source amounts and schedules. The article explains identity, biology and evidence. An archived schedule is not a clinically validated prescription, and a calculation cannot decide whether a compound is suitable for a person. Keep the exact molecule, , route and strength attached to any research claim. Do not treat an animal experiment as a human dosing instruction or transfer a prescription product's instructions to a different vial.
When checking a paper, first identify who or what was studied. Then check the comparison group, the measured outcome, the length of follow-up and reported adverse effects. A laboratory marker and a patient benefit are different endpoints. Small exploratory studies can help generate a hypothesis, while larger controlled studies can test it more reliably. Internal compound links provide comparisons, and the dotted terms open short definitions with links to the site's glossary. The source links below let you check the original context rather than relying on a headline.
Key facts
SOURCE DATA
Molecular formula
—
Molecular weight
—
CAS number
—
Sequence
—
Half-life
Not established for a general human-use regimen in the reviewed evidence.
Form
—
Storage
—
Reference vial sizes (not inventory)
10 mg, 20 mg
CJC component variant
CJC/IPA variant unresolved: the source CJC-1295 profile includes both DAC and no-DAC protocols. Its generic component relationship does not identify the blend variant.
Implied amount calculated from the Dosing Table's reported volume UNITS: 0.5 mg
Reported schedule: Once daily 5 days per week, preferably before bed on an empty stomach.
Source mass amounts and schedules are retained. Reviewed syringe conversions use the stated preparation; unresolved conversions are labeled unavailable. Not personal medical advice. Consult a qualified clinician for decisions about personal use.
U-100 units measure syringe volume. Source: November 6, 2026 revised reference.
Source reference for research and education. Not personal medical advice. Amounts and clinical suitability are not independently verified. Conversion checks are labeled below.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source-specific review note
Confirm the labeled total/component mass and ingredient ratio before loading this blend. The revised table does not establish its amount basis.
Source-specific review note
Confirm the labeled total/component mass and ingredient ratio before loading this blend. The revised table does not establish its amount basis.
Source-specific review note
Confirm the labeled total/component mass and ingredient ratio before loading this blend. The revised table does not establish its amount basis.
Source-specific review note
Confirm the labeled total/component mass and ingredient ratio before loading this blend. The revised table does not establish its amount basis.
Research discussion 0
Share a source, ask a question, or add context. Every comment is reviewed before it appears publicly.
Explore the peptide forum → for dedicated threads and nested conversations.
Save your research and join the conversation.
Sign in to comment